霍奇金淋巴瘤的治疗及BV、PD-1及CAR-T等新型方式对霍奇金淋巴瘤治疗的影响

霍奇金淋巴瘤在我国淋巴造血系统恶性肿瘤中相对少见，病理是以数量为1%左右的巨大肿瘤细胞(reed-sternberg, R-S)或结节性淋巴细胞增生为特点，免疫表型为缺乏典型抗原标志的B淋巴细胞。以往的传统治疗方法主要是放疗及以MOPP方案(氮芥、长春新碱、丙卡嗪、泼尼松)和ABVD方案(多柔比星、博来霉素、长春花碱、达卡巴嗪)为代表药物的化疗，复发患者采用加大剂量化疗或自体干细胞移植。随着对疾病发病机制及肿瘤微环境研究的深入，现已经开发出了针对肿瘤细胞的靶向治疗药如布伦妥昔单抗、维多汀（Brentuximab Vidocin,BV）及免疫检查点程序性死亡受体1抑制剂(programmed cell death protein 1, PD-1)，还有嵌合抗原受体T细胞（chimeric antigen receptor T-Cell, CAR-T），这些新选择的出现势必对疾病的转归发展及预后产生深远影响，以往的诊治指南及评估指标可能也需要发生变化，本文将对于几种新的药物在临床使用中的数据及文献研究做一综述。

The treatment of Hodgkin's lymphoma and the effects of BV, PD-1 and CAR-T on the treatment of Hodgkin's lymphoma

Hodgkin''s lymphoma is relatively rare among the malignant tumors of lymphohematopoietic system in China. The pathology is characterized by about 1% of giant reed-sternberg cells or nodular lymphocyte proliferation, and the immunophenotype is B lymphocytes lacking typical antigen markers. The traditional treatment methods were radiotherapy and chemotherapy such as MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), and Relapsed patients were treated with high-dose chemotherapy or autologous stem cell transplantation. With the in-depth study of disease pathogenesis and tumor microenvironment, targeted therapeutic drugs for tumor cells have been developed, such as brentuximab vidocin (BV) and immune checkpoint inhibitor, as well as chimeric antigen receptor T cells (CAR-T). The emergence of these new choices have a far-reaching impact on the outcome, development, and prognosis of the disease, and the previous diagnosis, treatment guidelines, and evaluation indicators may also need to be changed. This article reviewed the data and literature of some new drugs in the treatment of lymphoma.